Industry News

Collaboration Signed to Develop DNA-Based Cancer Products

Published in Cancer Weekly, July 4th, 2000

Coley Pharmaceutical Group, Wellesley, Massachusetts, and the Ludwig Institute for Cancer Research, Hilden, Germany, have established a clinical research collaboration for the development and evaluation of CpG DNA-based cancer products, the company announced.

CpG DNA molecules are novel immune stimulants that activate the immune system and may enhance the body's ability to fight cancer. Through the collaboration, Ludwig researchers will conduct early clinical studies designed to examine the safety and potential utility of CpG DNA-based products as stand-alone treatments for cancer, as well as in combination with several of Ludwig's proprietary tumor-specific antigens...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry